GLOW vs TB-500: What Is the Difference?
GLOW contains TB-500 — but because TB-500 is such a large molecule, it makes up far less of the blend than the label suggests.
In plain English
GLOW is a 70 mg blend of GHK-Cu (50 mg), BPC-157 (10 mg) and TB-500 (10 mg), studied as a combined preparation for skin and connective tissue.
TB-500 on its own is a lab-made fragment of a protein found in nearly every cell, studied around cell movement — how cells travel to where they are needed.
The difference, without the jargon
GLOW holds 10 mg of TB-500, the same as a typical standalone vial. But there is a subtlety worth knowing: TB-500 is by far the biggest molecule of the three, so while it is 14% of the vial by weight, it is only about 1% by actual molecule count. GHK-Cu, being tiny, makes up roughly 94% of the molecules present. If your research is specifically about cell movement, that matters — buying TB-500 alone gives you the compound without it being numerically swamped. Handling is simpler too. TB-500 alone needs darkness because of one oxygen-sensitive part. GLOW needs darkness plus neutral acidity plus no chelating agents, all inherited from the copper peptide that dominates it.
Common questions
Does GLOW contain TB-500?
Yes, 10 mg of it — the same as a typical standalone vial — alongside 50 mg GHK-Cu and 10 mg BPC-157.
Why is TB-500 such a small part of the blend by molecule count?
Because it is a large molecule. TB-500 weighs about 4963 units per molecule while GHK-Cu weighs about 340. So 10 mg of TB-500 contains far fewer individual molecules than 50 mg of GHK-Cu — roughly 1% of the total versus about 94%.
When would you choose TB-500 alone?
When cell movement is the specific mechanism being studied, and you want a result you can attribute to one compound. It is also simpler to store, needing only protection from light rather than the pH and chelator constraints that come with a copper-containing blend.
Technical reference below
How they actually differ
GLOW contains 10 mg of TB-500, the same as a typical standalone vial, alongside 50 mg GHK-Cu and 10 mg BPC-157. The twist is that TB-500 is by far the largest molecule of the three at 4963 g/mol, so despite being 14% of the fill by mass it is only around 1% by molecule count. If your research question is specifically about actin-mediated cell migration, that dilution matters — TB-500 alone gives you the compound without 50 mg of copper peptide dominating the preparation. Handling also differs: TB-500 alone needs light protection for its methionine, while GLOW additionally needs neutral pH and no chelators because of the GHK-Cu.
GLOW — origin
GLOW combines three of the most-studied compounds in tissue and dermal research into one 70 mg vial: GHK-Cu (50 mg), BPC-157 (10 mg) and TB-500 (10 mg). The rationale is mechanistic complementarity — GHK-Cu research centres on collagen and extracellular matrix synthesis, BPC-157 on angiogenesis and growth-factor signalling, and TB-500 on actin-mediated cell migration. Three non-overlapping routes into the same repair biology.
TB-500 (Thymosin Beta-4) — origin
TB-500 corresponds to the active region of Thymosin Beta-4, a 43-residue actin-sequestering protein present in virtually every mammalian cell type and abundant in wound fluid and platelets. Research interest followed the observation that the protein's activity in tissue-organisation models is largely retained by a short fragment of it.
GLOW research themes
The majority component, with the deepest dermal literature — collagen and glycosaminoglycan synthesis in fibroblast models.
Studied around vessel formation and growth-factor pathways in tissue-repair models.
Actin sequestration and directed cell movement — how cells reach a tissue defect.
The three components act through genuinely non-overlapping mechanisms, which is the rationale for combining them.
TB-500 (Thymosin Beta-4) research themes
The defining studied mechanism: binding G-actin and influencing the polymerisation equilibrium that governs cell motility.
Investigated in models where directed cell movement into a tissue defect is the measured endpoint.
Two of the better-populated preclinical literatures for the parent protein.
Studied for effects on inflammatory signalling in tissue-injury models.
GLOW handling
- Never reconstitute in acidic diluent — this dissociates copper from the GHK-Cu component, which is the majority of the vial.
- Keep chelating agents such as EDTA out of any buffer used with GLOW; they will strip the copper.
- Treat colour as data: clear, even blue is correct. Pale, colourless or green means the GHK-Cu component has degraded.
- Protect from light for the TB-500 and GHK-Cu components, and minimise headspace exposure.
- Do not subdivide the dry cake — three co-lyophilized components do not partition evenly in powder form.
TB-500 (Thymosin Beta-4) handling
- Minimise headspace exposure — each opening introduces oxygen that drives methionine oxidation.
- Keep reconstituted vials out of direct light, including bench lighting over long sessions.
- Introduce diluent against the vial wall; the cake is light and can be dispersed by a direct stream before it dissolves.
Both third-party tested
Every Popular Peptides batch of GLOW and TB-500 (Thymosin Beta-4) is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
GLOW reference
Related comparisons
GLOW and TB-500 (Thymosin Beta-4) are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.